<DOC>
	<DOCNO>NCT02012569</DOCNO>
	<brief_summary>The purpose study determine haemostatic efficacy TT-173 , reduce bleeding time donor site skin grafting .</brief_summary>
	<brief_title>Determine Haemostatic Efficacy TT-173 , Reducing Bleeding Time Donor Site Skin Grafting</brief_title>
	<detailed_description>As TT-113 clear use topical hemostatic agent , propose study investigate safety efficacy TT-113 donor site sking graft</detailed_description>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Subjects sign informed consent . Subjects undergo skin graft . Subjects sexes old 18 year . Subjects present burn traumatic skin injury affect less 30 % corporal surface . Subjects platelet count compatible pathology . Subjects present haemogram result indicative situation mention exclusion criterion . Subjects present biochemical result indicative situation mention exclusion criterion . Subjects present coagulation parameter indicative situation mention exclusion criterion . Women childbearing age take contraceptive measure willing maintain end follow study . Women childbearing age present negative test pregnancy moment study inclusion Subjects personal family history abnormal hemorrhagic episode . Subjects affect kind congenital acquire coagulopathies . Subjects present burn traumatic skin injury affect 31 % corporal surface . Subjects affect blood , heart liver disease , chronic renal failure , severe chronic obstructive pulmonary disease , active oncologic process past three month , diabetes type I suffer stroke . Subjects experience excessive bleeding surgical procedure , childbirth tooth extraction . Subjects affect acute infectious disease . Subjects affect systemic disease may worsen prognosis adverse effect occur ( decompensated type 2 diabetes mellitus , uncontrolled hypertension severe systemic disease ) . Subjects take antiplatelet therapy one week 48 hour surgery ( AAS , trifusal , dipiridamol , clopidogrel , abciximab ) . Subjects know hypersensitivity allergy component drug . Subjects consume abuse drug exclude cannabis derivative . Subjects unable follow understand properly instruction requirement study . Subjects free give inform consent mentally incapacitated discretion investigator . Subjects participate participate past three month another clinical trial drug treatment . Subjects investigator , collaborator , nurse , center employee person directly relate development protocol . Subjects positive HIV HCV serology , present active HBV infection . Subjects pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>skin grafting</keyword>
	<keyword>elective treatment</keyword>
</DOC>